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ABSTRACT
 Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma characterized by 
rapid disease progression. The needs for new therapeutic strategies for MCL patients 
call for further understanding on the molecular mechanisms of pathogenesis of MCL. 
Recently, long noncoding RNAs (lncRNAs) have been recognized as key regulators 
of gene expression and disease development, however, the role of lncRNAs in non-
Hodgkin lymphoma and specifically in MCL is still unknown. Next generation RNA-
sequencing was carried out on MCL patient samples along with normal controls 
and data was analyzed. As a result, several novel lncRNAs were found significantly 
overexpressed in the MCL samples with lncRNA ROR1-AS1 the most significant one. 
We cloned the ROR1-AS1 lncRNA in expression vector and ectopically transfected in 
MCL cell lines. Results showed that overexpression of ROR1-AS1 lncRNA promoted 
growth of MCL cells while decreased sensitivity to the treatment with drugs ibrutinib 
and dexamethasone. ROR-AS1 overexpression also decreased the mRNA expression 
of P16 (P = 0.21), and SOX11 (p = 0.017), without much effect on P53, ATM and P14 
mRNA. RNA-immunoprecipitation assays demonstrated high affinity binding of lncRNA 
ROR1-AS1 with EZH2 and SUZ12 proteins of the polycomb repressive complex-2 
(PRC2). Suppressing EZH2 activity with pharmacological inhibitor GSK343 abolished 
binding of ROR1-AS1 with EZH2. Taken together, this study identified a functional 
lncRNA ROR-AS1 involved with regulation of gene transcription via associating with 
PRC2 complex, and may serve as a novel biomarker in MCL patients.
INTRODUCTION
 Mantle cell lymphoma (MCL) is an aggressive 
B-cell malignancy usually diagnosed as a late-stage 
disease with patients above 60 years old. Although the 
median survival of MCL patients has increased with 
the development of new therapeutic strategies [1, 2], 
MCL has been regarded as an incurable blood cancer 
that is characterized by rapid disease progression. The 
constitutive overexpression of cyclin D1 caused by 
t(11;14) (q13;q32) translocation is considered to be the 
initial oncogenic steps for the development of MCL [3]. 
Certain key genes in cell cycle pathway (INK4a, RB1, 
and ARF), and in DNA damage response pathways (ataxia 
telangiectasia mutated (ATM and TP53) are frequently 
deregulated, deleted or mutated [4-7]. More recently, 
the transcription factor SOX11 has been identified as a 
specific marker for both Cyclin D1 positive and negative 
MCL and regarded as a key gene in the pathogenesis of 
MCL [8, 9]. 
 Although the clinical outcome of MCL patients 
has been improved with the adjustment of the treatment 
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protocol according to the heterogeneous biology and 
clinical presentation, relapses and progressive resistance 
to treatment are common. Therefore, new therapeutic 
strategies based on understanding of the molecular 
mechanism of pathogenesis are in great need. Long 
noncoding RNAs (lncRNAs) are RNA transcripts with a 
length ranging from 200 bases to more than 20 kilo base 
that lack protein-coding capacity, and may have different 
origins related to coding gene in chromosome such as 
intronic, exonic, intergenic, intragenic, promoter regions, 
enhancer sequences and antisense strand [10]. Unlike 
protein coding RNA transcripts, which are exported to the 
cytoplasm, most of the lncRNAs are retained within the 
nucleus. LncRNAs retained in the nucleus are potentially 
targeted for nuclear genome surveillance and transcription 
machinery. Some of the key biological processes regulated 
through lncRNAs include epigenetic and transcriptional 
regulation of gene expression [11, 12], post-transcriptional 
regulation such as mRNA processing, and translation [13-
18], cell differentiation and development [19] and human 
disease especially the cancer [20]. LncRNA profile in 
B cell lymphoma and specifically in MCL has not been 
identified or mechanistically studied. In this study, we 
aimed to identify the lncRNAs deregulated in MCL and 
explore their role in MCL pathogenesis. 
RESULTS
Identification of lncRNAs profile in MCL by next 
generation RNA-sequencing
To identify lncRNAs profile in MCL, we performed 
next generation RNA-sequencing and compared the 
lncRNA expression in MCL patient samples with non-
lymphoma control samples. For sorted lncRNAs, we used 
log2 fold changes greater than 10 and p-value less than 
0.05. Based on these criteria we identified ten different 
lncRNAs upregulated in MCL patient samples with 
ROR1-AS1 (also called RP11-24J) on the top of the list 
(Figure 1A). To validate findings from RNA-sequencing, 
expression of ROR1-AS1 in patient samples and normal 
controls was further analyzed by quantitative RT-PCR. 
Results show that ROR1-AS1 is overexpressed (more 
than 50 folds) in most of the MCL tumor samples as 
compared to the normal controls (Figure 1B), although 
due to the small sample size p value was not significant 
(p = 0.16). Furthermore, MCL cell lines (Mino, Granta, 
JVM2 and Z138) also express higher levels of ROR1-AS1 
as compared to normal controls, although the expression 
Figure 1: LncRNA profile in MCL. A.-B. LncRNAs profile in MCL patient samples identified by next generation RNA-sequencing. 
Top 10 LncRNAs expression and their characteristics in cells from MCL patient versus non-lymphoma control (n = 5) are shown. (B) 
Confirmation of ROR1-AS1 lncRNAs in MCL samples and cell lines was done by QRT-PCR using specific primers. Bar diagram showing 
mean of ROR1-AS1 expression in normal controls (n = 5), MCL patient samples (n = 5) and MCL cell lines (n = 4). 
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in MCL cell lines was relatively low as compared to the 
MCL patient samples. Collectively, we have identified 
lncRNA transcripts upregulated in MCL patient samples 
with ROR1-AS1 as prominent candidate. 
LncRNAs ROR1-AS1 and AC006196 are 
predominantly localized in the nucleus
One of the important factors in understanding the 
function of lncRNAs is their intracellular location. We 
separated cytosol RNA from nuclear RNA and checked the 
localization of the lncRNAs ROR1-AS1 and AC006196 
in MCL cell lines, Mino and Z138. QRT-PCR data from 
fractionated RNA species clearly showed that lncRNA 
ROR1-AS1 and AC006196 found in Mino and Z138 cells 
were predominantly localized within the nucleus (Figure 
2A-2B). To ensure purity of fractionation β-actin and U6 
mRNA were assessed as markers of cytosolic and nuclear 
RNA transcripts, respectively. As shown in Figure 2C-D, 
about 90% of β-actin transcripts in both Mino and Z138 
cell lines were in the cytosolic fraction while 80-90% of 
U6 mRNA transcripts localized in the nuclear fraction 
(Figure 2C-2D). These results indicate that lncRNA 
ROR1-AS1 and AC006196 are localized in the nucleus 
and likely to be involved in epigenetic regulation of gene 
transcription rather than protein translation or transport. 
The biological functions of the MCL associated 
lncRNAs
We next tested if the MCL associated lncRNAs (as 
shown in Figure 1A) have any biological relevance or 
affect the growth of the MCL cells. We cloned 3 lncRNAs 
ROR1-AS1, RP11-12A and AF12791 into mammalian 
expression vector, pcDNA3.1. Transient transfection 
with lncRNA expression vectors in MCL cell line Mino 
increased expression of corresponding lncRNAs several 
hundred folds over the base line (Supplementary Figure 
1A-1B). As shown in Figure 3A, overexpression of 
RP11-12A in Mino cells had no significant impact on cell 
proliferation, while overexpression of lncRNAs ROR1-
AS1 and AF127936.5 enhanced 3H-thymidine uptake by 
Figure 2: Subcellular distribution of lncRNAs ROR1-AS1 and AC006196 in MCL. A.-D. Bar graphs represent relative RNA 
quantity in cytosolic versus nuclear fraction for the lncRNA ROR1-AS1 (A), AC006196.1 (B) in Mino and Z138 cell lines, levels of U6 
mRNA (C) and Actin mRNA (D) were used as controls to check purity of the nuclear and cytosolic fractions, respectively. Cytoplasmic 
RNA and nuclear fraction of RNA were extracted, and the expression of each the RNA quantified by QPCR. Experiment was repeated 2 
times with similar results.
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Figure 3: The effect of lncRNAs overexpression on cell growth. A.-B. Bar graphs showing relative 3H-thymidine incorporation 
as a measure of proliferation in Mino cells transfected with empty vector, or vector with expression cassette for lncRNAs, ROR1-AS1, 
RP11-12A2.3 or AF127936.5. Bars represent mean of 4 independent measurements and compared by t-test, ROR1-AS1 (p = 0.0000005), 
RP11-12A2.3 (p = 0.01), AF127936.5 (p = 0.006). (B) Bar graphs depicting effects of the ROR1-AS1 on proliferation (3H-thymidine 
incorporation) in Mino, Granta, and JVM2 cells. Bars represent mean of 3 independent measurements and compared by t-test, Mino (p = 
0.000007), Granta (p = 0.00007), JVM2 (p = 0.00006). C. The effect of CD40L (p = 0.002) and IgM (p = 0.02) on the expression of ROR1-
AS1 in CD19+ normal B cells by QPCR.
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5 and 2 folds, respectively (Figure 3A). Thus, our results 
suggest that lncRNA ROR1-AS1 may have an oncogenic 
effect in MCL cells. To further validate this notion, the 
effect of ROR1-AS1 overexpression was tested in two 
more MCL cells lines, Granta and JVM2. Consistently 
overexpression of ROR1-AS1 in both of additional MCL 
cell lines was associated with increased 3H-thymidine 
uptake (Figure 3B). On contrary, silencing the expression 
of ROR1-AS1 by siRNA decreased 3H-thymidine in 
Granta cell line as compared to non-targeting siRNA 
controls (Supplementary Figure 2A-2B). Taken together, 
these results suggest that deregulation of lncRNA in MCL 
patient samples is in part responsible for sustained growth 
of MCL cells. 
 B cell receptor (BCR) signaling is very important in 
B-cell development and maturation and the pathogenesis 
of B cell lymphoma including MCL [21]. To explore 
whether the lncRNAs are involved in BCR signaling, we 
isolated B cells from peripheral blood with CD19 antibody 
and treated with CD40L and IgM. QRT-PCR data showed 
that lncRNA ROR-AS1 was induced with the treatment 
of CD40L and IgM (Figure 3C). These data indicated the 
lncRNA ROR-AS1 is likely involved in the B cell receptor 
signaling. 
The interaction of lncRNA ROR-AS1 with 
polycomb repressive complex
LncRNAs especially those localized with in the 
nucleus have been previously linked to the epigenetic 
control of transcriptional regulation through their 
association with chromatin remodeling factors such 
as polycomb repressive complex 2 (PRC2) [22]. We 
examined whether ROR1-AS1 physically associates with 
the PRC2 subunits EZH2, SUZ12 and EED. Results from 
RNA-immunoprecipitation (RNA-IP) with antibody to 
EZH2 and subsequent analysis demonstrate a high affinity 
binding of lncRNA ROR1-AS1 with EZH2 in three 
different MCL cell lines (Figure 4A). Furthermore, RNA-
IP performed with antibodies to EED and SUZ12 also 
showed binding of ROR1-AS1 lncRNA with EED and 
SUZ12 (Figure 4B). These results suggest that ROR1-AS1 
interacts with PRC2, whether interaction between ROR1-
AS1 and PRC2 depends on PRC2 activation was however, 
was unclear. To address this question, we used GSK343, a 
potent and selective inhibitor of the EZH2 activity [23]. As 
shown in Figure 4C, interaction between ROR1-AS1 and 
EZH2 was blocked in cells pretreated with GSK343, while 
a robust binding occurred in untreated controls (Figure 
4C). Collectively, these data suggest that lncRNA ROR1-
AS1 interaction between lncRNA ROR1-AS1 and PRC2 
complex may be involved in the epigenetic regulation of 
gene transcription in MCL cells.
Effect of ROR1-AS1 on the key genes involved in 
MCL pathogenesis
To study the functional role of lncRNA ROR1-AS1 
in MCL cells, we checked if overexpression of ROR1-
AS1 modulates the expression of key genes involved in 
the pathogenesis of MCL [3, 24]. We specifically assessed 
the effect of ROR1-AS1 overexpression on cyclin D1, p14 
(ARF), p16 (INK4a), ATM, p53 and SOX11. QRT-PCR 
data showed no significant impact of ROR1-AS1 ectopic 
transfection on expression of cyclin D1 (P = 0.21) and 
ATM (P = 0.67), but the expression of the SOX11 was 
suppressed significantly 56% (p = 0.017) in Mino cells as 
compared to vector alone (Figure 5A). We then evaluated 
effect of ROR1-AS1 on tumor suppressor genes such as 
P14, P16 and P53 involved in the pathogenesis of MCL. 
QRT-PCR data indicated only modest effect on expression 
of p16 (P = 0.21), however, there was no effect observed 
on the expression of P14 and P53 (Figure 5B). These 
data suggest that ROR-AS1 might regulate expression of 
SOX11 and P16 in MCL cells.
Effect of ROR-AS1 on drug sensitivity
Some of the lncRNAs have been previously shown 
to render resistance to chemotherapy drugs [25]. We 
assessed the impact of lncRNA ROR-AS1 overexpression 
on sensitivity of MCL cells to the chemotherapeutic drugs 
bendamustine, dexamethasone and FDA approved, B cell 
receptor pathway drug ibrutinib. Results demonstrate that 
in Mino cells expressing empty vector treatment with 10 
or 50 µM bendamustine decreased 3H-thymidine uptake by 
as 50 and 80%, respectively compared to vehicle control, 
ROR-AS1 overexpression had no significant impact on 
sensitivity to bendamustine (Figure 6A). Sensitivity to 
dexamethasone or ibrutinib in Mino cells led to a 50-75% 
decline in 3H-thymidine uptake in vector expressing cells. 
Interestingly proliferation inhibition by dexamethasone or 
ibrutinib was attenuated by overexpression of ROR-AS1 
(Figure 6B-6C). This data suggested that lncRNA ROR-
AS1 overexpression modulates sensitivity of MCL cells to 
therapeutic drugs and thus could influence the prognosis 
of MCL patients. 
 DISCUSSION
 Non-Hodgkin lymphoma is the seventh most 
common cancer in men and women. Mantle cell 
lymphoma (MCL) is a unique genetic and clinical subtype 
of NHL with a heterogeneous prognosis. Patients with 
MCL have a variable clinical course and in most cases 
disease eventually relapse, and median survival for MCL 
patients remains approximately 7 years [26, 27] Even 
though tremendous efforts have been made to optimize 
treatment, the progress in improvement in prognosis 
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Figure 4: Analysis of interaction between lncRNA ROR1-AS1 and PRC2 complex. A.-C. Representative gels pictures 
showing enrichments of ROR1-AS1 after RNA-IP with EZH2 antibody or IgG in lysates of Mino, Granta and Z138 cells, 1% of input 
was analyzed as qualitative control and 18S RNA was used as loading control. (B) Gels pictures showing enrichment of ROR1-AS1 after 
RNA-IP with EED or SUZ12 antibodies or IgG in lysates of Mino cells, 1% of input and 18S RNA are shown as controls. C) Gel pictures 
showing effect of EZH2 inhibition on enrichments of ROR-AS1 after RNA-IP with EZH2 antibody. RNA-IPs were performed on lysates 
from Mino cells pretreated with and without 10 µM GSK343, 1% of input was analyzed as qualitative control and 18S RNA was used as 
loading control. 
Oncotarget80229www.impactjournals.com/oncotarget
of MCL patients has been slow. New insights into the 
pathobiology of MCL, in addition to identify novel 
biomarkers and therapeutic targets are desperately needed. 
A better understanding of the mechanisms underlying 
the pathogenesis of MCL is important for improvement 
of therapy. Long noncoding RNAs (lncRNAs) such as 
HOTAIR and MALAT1 have been shown to be involved 
in the development of breast and lung cancer [28, 29], 
however, role of lncRNAs in lymphoma is still unknown. 
In this study, we analyzed lncRNA profile in MCL patients 
by next generation RNA sequencing and revealed for the 
first time that ROR1-AS1 lncRNA is highly upregulated 
in cells from MCL patients. Our analysis further showed 
that lncRNA ROR1-AS1 is predominantly localized in 
the nucleus, and physically associates with core proteins 
of PRC2 complex such as EZH2 and SUZ12. These 
results are consistent with prior reports suggesting role of 
HOTAIR lncRNA in chromatin reprograming by targeting 
PRC2 [29]. Our results further revealed that ROR1-
AS1 overexpression is associated with increased cell 
proliferation suggesting a pivotal role for this lncRNA in 
chromatin reprogramming that contributes towards growth 
advantage in MCL cells. We demonstrate that EZH2 
inhibition through pharmacological inhibitors abolished 
the interaction between ROR1-AS1 and EZH2, which 
further supports the notion that ROR1-AS1 interaction 
with EZH2 may impact activity of PRC2 complex. A 
number of lncRNAs has been shown to interact with 
EZH2 and regulate target gene expression. HOTAIR 
interacts with PRC2 and regulates HOXD locus and other 
target genes of EZH2 subunit [30]. Similarly, ANRIL 
lncRNA was found to recruit EZH2 to suppress INK4b/
ARF/INK4a expression [28]. Thus, our results support the 
notion that LncRNA partner bound to EZH2 might help 
targeting of PRC2 complex to specific gene loci. Whole 
exome sequencing in MCL identified significantly mutated 
genes including known drivers of MCL malignancy such 
as ATM, Cyclin D1 and tumor suppressor gene TP53 
[31]. However, overexpression of lncRNA ROR1-AS1 
does not seem to impact expression of these transcripts. 
SOX11 is regarded as a prognostic marker in many 
different kinds of cancers especially the MCL [32-36]. 
Recently, transcriptional activity of SOX11 was implicated 
in biological processes including B-cell differentiation, 
tumor angiogenesis, and overall pathogenesis of MCL [37-
40]. However, evidence in literature suggest that decreased 
expression of SOX11 associates with worse prognosis of 
MCL [35, 41]. While nuclear acculturation of  SOX11 has 
been developed as a specific biomarker for MCL patients 
[8, 9, 42-44] but prognostic value of SOX11 and its role 
in disease progression is not well founded. Furthermore, 
the mechanism of transcriptional regulation of SOX11 in 
MCL remains unclear. Present study suggest that lncRNA 
ROR-AS1 in association with PRC2 complex influence 
transcription of SOX11. 
 In summary, our studies have identified for the 
first time the lncRNA profile in MCL cells and identified 
a ROR1-AS1 overexpression in MCL cells. The present 
Figure 5: The effect of lncRNA ROR1-AS1 overexpression on transcription of key genes in MCL . A.-B. Bar graphs 
depicting relative mRNA transcript of cyclin D1, ATM, SOX11 (A) and (B) p14, p16, p53 in Mino cells transfected with empty vector, or 
vector with expression cassette for lncRNAs ROR1-AS1. mRNA transcripts were analyzed by Q-RTPCR using gene specific primers. Each 
bar represent mean of 4 independent measurements and comparisons are based on paired t-test, (A) cyclin D1 (P = 0.21), ATM (P = 0.67), 
SOX11 (0.017); (B) p14 (P = 0.41), p16 (P = 0.21), p53 (P = 0.73). 
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Figure 6: The effect of ROR1-AS1 overexpression on the sensitivity of MCL cells to chemotherapy drugs. A.-C. Bar 
graphs showing effects of dexamethasone (A), bendamustine (B) and Ibrutinib (C) on proliferation (3H-thymidine incorporation) of Mino 
cells transfected with either empty vector or vector with ROR-AS1 expression cassette.
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work establishes that ROR1-AS1 mediates MCL growth 
through histone modification via EZH2. Such information 
provides new insights into the function and mechanisms 
of ROR1-AS1 in MCL pathogenesis. Whether lncRNA 
ROR1-AS1 is able to bind and regulate other histone 
modification complex such as chromatin modifier WHSC1 
and MLL2 and induce gene suppression in an EZH2-
independent mechanism remained to be investigated. 
Similarly, ROR1-AS1 may regulate multiple other 
targets, which may contribute to MCL pathogenesis or 
chemo-resistance remains the subject for future studies. 
Nevertheless, our results set a foundation for future 
discoveries of novel modulators of MCL pathogenesis, and 
likely to lead us to therapeutic targets and/or biomarkers of 
critical importance.
MATERIALS AND METHODS
Cell lines, drugs and MCL samples
The mantle cell lymphoma (MCL) cell lines Mino, 
Granta, JVM2 and Z138 were purchased from ATCC 
(Manassas, VA, USA). These cell lines were cultured 
in Roswell Park Memorial Institute medium (RPMI) 
supplemented with 10% fetal bovine serum (FBS). 
HEK-293T cell line purchased from Open Biosystem 
(Huntsville, AL, USA) was grown in the Dulbecco’s 
Modified Eagle Medium supplemented with 10% FBS. 
Drugs dexamethasone and bendamustine were procured 
from Sigma-Aldrich, BTK inhibitor ibrutinib was 
purchased from Selleckchem.  Mononuclear cells from 
MCL patients (n = 5) and normal control (lymph nodes) 
(n = 5) were provided by Mayo Clinic/Iowa Lymphoma 
SPORE.
Antibodies
Antibodies to EZH2, EED, and SUZ12 were 
purchased from Abcam (Cambridge, MA USA).
RNA-sequencing and bioinformatics analysis
RNA was extracted using Trizol reagent (Life 
Technologies) and sent to the Mayo Clinic Molecular 
Biology Core for RNA-sequencing to identify lncRNAs. 
The lncRNA expression was analyzed by bioinformatics 
tool ICQ-lincRNA developed at the Mayo Clinic. This 
computational pipeline integrates three consecutive steps: 
candidate transcript assembly, LincRNA identification, 
and annotation and visualization of LincRNAs. 
Plasmid construction
lncRNAs ROR1-AS1, AF127936.5 and RP11-
12A2.3 were amplified using cDNA of Mino cells as 
template and cloned into vector IDT Smart (IDT). To 
construct the expression cassette, the respective lncRNA 
was extracted by restriction digestion of the carrier vector 
IDT Smart using BamHI (5’) and NotI (3’) and cloned in 
the expression vector pcDNA3.1 using T4 DNA Ligase 
(NEB, cat. no. M0202S). Plasmids were screened by 
restriction digestion, and subsequently confirmed by 
sequencing. 
Small interfering RNA (siRNA) and cell 
transfection
ROR1-AS1 siRNA was purchased from Dharmacon 
(Lafayette, CO, USA). Mino, Granta and JVM2 cells were 
transfected for 48 hours with ROR1-AS1 siRNA using 
Amaxa Nucleofector Kit (Lonza, Walkersville, MD, USA) 
as per instruction manual. For lncRNA overexpression 
Mino, Granta and JVM2 cells were transfected with 5 
µg of plasmid (pcDNA3.1 empty vector or pcDNA3.1- 
ROR1-AS1, pcDNA3.1-AF127936.5, pcDNA3.1-RP11-
12A2.3) using Amaxa Cell Line Nucleofector Kit and 
incubated for 24-48 hours prior to any analysis. 
Cell proliferation assay
Granta, Mino and JVM2 cells transfected with 
lncRNA ROR1-AS1 construct or empty vector were 
seeded into 96-well plate in 4 replicates (0.1 million/200 
µl/well) and proliferation evaluated by 3H-thymidine 
incorporation assay as previously described [45].
Extraction of cytoplasmic and nuclear RNA
Cytoplasmic and nuclear RNA were extracted 
using the Cytoplasmic and Nuclear RNA Purification Kit 
(Norgen, Thorold, Ontario, Canada) as per instruction 
manual. Briefly, 5-10 million cells were washed with PBS, 
centrifuged and cell pellet was subsequently lysed in 1 
ml of lysis buffer and centrifuged at 14000 rpm at 4°C. 
Supernatant was used to extract cytoplasmic RNA, and the 
pellet processed for extraction of nuclear RNA. 
RT-PCR and quantitative RT-PCR (QRT-PCR)
RNA was extracted from 2 million cells with the 
RNeasy Mini Kit (QIAGEN, Germantown, MD, USA), 
cDNA synthesized with SuperScript III First-Strand 
Synthesis SuperMix (Invitrogen) and subjected to PCR or 
Quantitative PCR (Q-PCR) as previously described [18]. 
Oncotarget80232www.impactjournals.com/oncotarget
The primers used are: 




AC006196.1-F 5’ GATGACAGAGGATGTTCGAC 
3’ 
AC006196.1-R 5’ CTGATGGAGGTATAGGAGTG 
3’
Cyclin D1-F 5’ ACACTTCCTCTCCAAAATGCC 
3’ and 
Cyclin D1-R 5’ GAGGGCGGATTGGAAATGAAC 
3’ ; 
P16-m-F 5’ GAAGGTCCCTCAGACATCCCC 3’ 
and 
P16-m-R 5’ CCCTGTAGGACCTTCGGTGAC 3’; 
p14-m-F 5’ CCCTCGTGCTGATGCTACTG 3’ and 





P53-m-F 5’ CCCAAGCAATGGATGATTTGA 3’ 
and 
P53-m-R 5’ GGCATTCTGGGAGCTTCATCT 3’; 
SOX11-m-F 5’ GCGCTGTTTGAAGCTTGTCG 3’ 
SOX11-m-R 5’ TATCTCCACCAACTCCCTAG 3’ .
RNA-immunoprecipitation (RNA-IP)
RNP-IP was performed with Magna RIP RNA-
Binding Protein Immuno-precipitation Kit (Millipore, cat 
#17-700) as previously described [18]. Briefly, 50 - 80 
million cells were lysed in 200µl RIP lysis buffer before 
the lysate was immuno-precipitated with EZH2, EED, 
SUZ12 antibody (or IgG) attached to protein-A magnetic 
beads. After the digestion with proteinase K, the RNA 
was purified by phenol chloroform extraction. The RNA 
dissolved in 20 µl RNAse-free water for further analysis 
by RT-PCR. 
Statistical analyses
Unless stated otherwise data is presented as Mean 
± SEM. Data was statistically analyzed using two-tailed 
Student’s t test, p value < 0.05 considered significant.
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